摘要
目的研究乙型肝炎病毒(HBV)基因型与聚乙二醇干扰素(PEG-IFN)疗效关系及不同基因型治疗后的肝脏病理改变。方法采用实时荧光PCR基因分型法,分析48例用聚乙二醇干扰素治疗的CHB患者基因型对抗病毒疗效的影响和病理改变情况。结果在治疗结束时,B型与C型对比,两种基因型的ALT复常率、HBeAg阴转率、HBeAg转换率、HBVDNA转阴率及病理结果改善率无明显差异(P>0.05);在随访48周后,B基因型的持续应答率明显高于C基因型(P<0.05)。结论HBV基因型是预测聚乙二醇干扰素疗效的重要因素,B基因型的持续应答率明显高于C基因型。
Objective To study the correlation of HBV genotypes to the response to PEG-interferon alpha （PEG-IFN） in chronic hepatitis B （CHB） patients. Methods Real-time fluorescent PCR was used for HBV genotyping in 48 CHB patients, and the therapeutic effects of PEG-WN and hepatic pathplogical changes were observed. Results No obvious differences were noted in ALT and HBV DNA levels or negative rate for HBeAg between patients with genotypes B and C （P〉0.05）. The sustained response rate was significantly higher in genotype B than in genotype C patients 48 weeks o after the therapy. Conclusion HBV genotype is the main factor for predicting PEG-WN therapy response in CHB patients, and the sustained response rate is significantly higher in genotype B than in genotype C patients.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2008年第7期1217-1218,1222,共3页
Journal of Southern Medical University
基金
国家973计划子课题(G19990541106)
